Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | VEGFA | P15692 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532739 | 0.90 | KDM4E (0.52) | STSKDM4EPKMLMNATP53 | |
| SCHEMBL20015397 | 0.88 | FAAH (0.66) | STSMEN1KMT2ANPSR1USP2 | |
| SCHEMBL16113579 | 0.88 | GPR119 (0.61) | MEN1KMT2AKDM4EPKMFAAH | |
| SCHEMBL12263494 | 0.88 | KDM4E (0.53) | KDM4EPKMTP53GPR119 | |
| SCHEMBL2250178 | 0.88 | GPR119 (0.60) | KDM4EPKMALDH1A1TP53GPR119 | |
| SCHEMBL13717007 | 0.87 | KDM4E (0.53) | MEN1KMT2AKDM4EPKMTP53 | |
| SCHEMBL3145386 | 0.87 | KDM4E (0.52) | STSKDM4EPKMLMNATP53 | |
| SCHEMBL4773737 | 0.87 | KDM4E (0.52) | KDM4EPKMHTTALDH1A1TP53 | |
| SCHEMBL578839 | 0.87 | FPR2 (0.53) | KDM4EPKMTP53CCR3GPR119 | |
| SCHEMBL4773466 | 0.87 | TP53 (0.54) | MEN1KMT2AKDM4EPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028808-A1 | AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS | RAPPTA THERAPEUTICS OY (FI) | 2024-02-08 | — | — | WO | disclosed |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| EP-1465631-B1 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1453804-B1 | CCR-3 RECEPTOR ANTAGONISTS VII | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| EP-1453804-B1 | CCR-3 RECEPTOR ANTAGONISTS VII | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-7019007-B2 | CCR-3 receptor antagonists (I) | SYNTEX (U.S.A.) LLC (US) | 2006-03-28 | — | — | US | disclosed |
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1453804-A2 | CCR-3 RECEPTOR ANTAGONISTS VII | F. Hoffmann-La Roche AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| EP-1453825-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| US-20030153578-A1 | CCR-3 receptor antagonists (I) | SYNTEX (U.S.A.) LLC | 2003-08-14 | — | — | US | disclosed |
| WO-2003045917-A2 | CCR-3 RECEPTOR ANTAGONISTS VII | F. HOFFMANN-LAROCHE AG (CH) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003045937-A1 | N-UREIDO-PIPERIDINES AS ANTAGONISTS VIII FOR CCR-3 RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-05 | — | — | WO | disclosed |
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2003-01-23 | — | — | US | disclosed |
| US-6476041-B1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | STS 4803/4885MEN1 4556/4885KMT2A 3093/4885 |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | STS 2383/4885MEN1 4340/4885KMT2A 2079/4885 |
| US-20030018038-A1 | 1,4 substituted piperidinyl NMDA/NR2B antagonists | GRIN1, GRIN2A, GRIN2B | STS 4637/4885MEN1 4657/4885KMT2A 705/4885 |
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | STS 4608/4885MEN1 769/4885KMT2A 3584/4885 |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | STS 1622/4885MEN1 4670/4885KMT2A 2134/4885 |
| US-20030153578-A1 | CCR-3 receptor antagonists (I) | CCR1, CCR3, CCR4 | STS 4814/4885MEN1 4093/4885KMT2A 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.